Medtronic

Medtronic rose 1.46% to close at $83.21 today, with an intraday peak of $83.56 at 11:17 ET, driven by strong fourth-quarter earnings and recent product innovations. Q4 EPS reached $0.97, up 18.27% year-over-year, while operating revenue hit $9.807 billion (up 9.86% YoY) and net profit reached $1.244 billion (up 17.8% YoY), demonstrating solid momentum in core operations. Recent FDA clearances for the Hugo robotic surgery AI navigation enhancement, the ION-L™ spinal navigation system, the TMR1370 ultra-low-power magnetic switch chip, and the completion of the SPR acquisition to expand minimally invasive pain treatment solutions underscore strengthened innovation momentum. From a valuation perspective, the stock has declined 13.37% year-to-date and fallen 21.74% from its 52-week high of $106.33, but trades 13.5% above the 52-week low of $73.31, with a solid 3.43% dividend yield providing support. However, the P/E ratio of 22.19 reflects continued market caution regarding growth prospects.

Medtronic closed marginally higher at $82.01 after pre-market weakness to $81.54, though intraday reached $82.845 at 10:54 ET, suggesting underlying buying support. Q4 earnings showed solid growth with EPS up 18.27% year-over-year to $0.9697, operating revenue up 9.86% to $9.807 billion, and operating income surging 48.39%, reflecting significant improvement in core profitability. The company won FDA approval for its Hugo robotic surgery AI application and completed the SPR acquisition expanding non-opioid pain treatment options, demonstrating solid strategic execution. The stock trades 22.87% below its 52-week high and is down 14.62% year-to-date with PE of 21.87x, reflecting reasonable valuation.

Medtronic displayed a mixed session today with pre-market strength fading through the regular session—reaching an intraday high of $83.08 in pre-market trading before sliding to a low of $81.53 during regular hours, ultimately closing at $81.89, then declining further to $81.73 in post-market trading for a net loss of around 0.75%. The pullback may reflect profit-taking following prior gains, compounded by recent litigation challenging FDA's regulatory oversight of spinal cord implants. The earnings fundamentals remain supportive—Q4 2026 operating income surged 48.39% year-over-year to $2.162 billion with net income up 17.8%, while the company secured FDA clearance for the Hugo robotic surgery AI application and completed the SPR acquisition to expand its non-opioid pain treatment portfolio. Nevertheless, valuations remain under pressure, with year-to-date performance down 14.74% and the stock trading 22.99% below its 52-week high of $106.33, at a PE multiple of 21.83x.

Medtronic declined 1.14% to $82.35 in US trading today, retreating from a pre-market peak of $83.95 as profit-taking pressures led to intraday volatility. The company's latest Q4 earnings remain constructive, with EPS of $0.97 up 18.27% year-over-year and revenue of $9.807 billion up 9.86%, demonstrating solid growth momentum in core business segments. Recent positive catalysts include FDA clearance for the Hugo robotic surgery AI-assisted application and completion of the SPR acquisition, which expands the company's non-opioid pain management portfolio. From a valuation standpoint, however, Medtronic has declined 14.26% year-to-date and trades 22.55% below its 52-week high of $106.33. The stock currently sits slightly below its 20-day moving average of $81.74, signaling market caution despite the company's operational improvements. Additionally, a recent FDA recall of the Harmony delivery catheter system may continue to weigh on investor sentiment near term.

Medtronic closed essentially flat today at $83.29, up just 0.11% from the prior close of $83.20, after premarket activity touched a high of $83.87 before consolidating during the regular trading session. Despite a series of recent positive catalysts—including the completion of the SPR acquisition to expand the non-opioid chronic pain treatment portfolio, the launch of the TMR1370 ultra-low-power magnetic switch IC targeting continuous glucose monitoring devices, and co-leading RapidPulse's oversubscribed Series B financing round—the stock continues to face persistent headwinds. Trading 21.67% below its 52-week high of $106.33 set on November 26, 2025, and down 13.28% year-to-date, the stock's underlying valuation pressures remain evident. However, the stock has rebounded 13.61% from its June low of $73.31 and continues to trade above both its 20-day moving average of $81.58 and 60-day moving average of $79.63, maintaining near-term technical support despite broader challenges.